https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36033 Wed 29 Jan 2020 11:59:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49974 Wed 28 Feb 2024 16:14:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33269 Wed 27 Apr 2022 14:49:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45130 Wed 26 Oct 2022 12:58:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44991 Wed 26 Oct 2022 09:28:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33724 Wed 24 May 2023 12:09:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53341 Wed 22 Nov 2023 10:19:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43392 Wed 22 Mar 2023 15:32:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48569 Wed 22 Mar 2023 15:26:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41799 .05) in survivors pre-diagnosis, after adjusting for confounders; however, the compliance score increased during postdiagnosis, with the mean difference score being significantly higher in recent survivors (0-3 years post diagnosis; MD = 0.055, P < .01). Likewise, within cancer survivors, the mean compliance score significantly increased 0-3 years postdiagnosis (MD = 0.07, P < .05) compared to pre-diagnosis, but this significant improvement was not maintained over the longer term (MD = 0.037, P > .05). Conclusion: In this sample, survivors had higher MHB score than controls. A cancer diagnosis may provide a teachable moment for health behavior change in the period immediately following diagnosis, but this effect was not sustained during longer-term survivorship.]]> Wed 22 Feb 2023 15:02:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33815 Wed 19 Jan 2022 15:18:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36509 Wed 15 Dec 2021 16:07:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47147 post hoc cost-effectiveness analysis was undertaken. Part A: patient-level cost and health effect data (Multidimensional Fatigue Inventory (MFI) scores) were derived from the MIDAS trial and analysis undertaken from a health-system perspective. Part B: a secondary analysis simulated the societal impact of modafinil therapy in terms of national productivity costs. Results: Part A: Mean cost of modafinil treatment was AUD$3.60/day/patient for a minimally clinically important change (10 points) in total MFI fatigue score, i.e., AUD$0.36/day/unit change in fatigue score per patient. For the base case scenario, the ICER of using modafinil (versus placebo) was AUD$131.73 ($90.17 - 248.15, for minimum and maximum costs, respectively). Part B: The potential productivity cost-savings to society were calculated as nearly AUD$467 million over 1 year, and up to $383,471,991,248 over 10 years, from the widespread use of modafinil treatment in the Australian population of working-age stroke-survivors, representing a significant societal benefit. Conclusions: Modafinil is a highly cost-effective treatment for post-stroke fatigue, offering significant productivity gains and potential cost-savings to society from the widespread use of modafinil treatment in the Australian population of working-age stroke-survivors.]]> Wed 14 Dec 2022 15:27:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47086 0.05). Similar results were found for IBS subtypes. Higher serum L-arginine concentration had the strongest association with IBS diagnosis, with an odds ratio of 9.03 for those with serum L-arginine at the 75th (84 μmol/L) versus 25th (46 μmol/L) percentile (95% CI: 5.99–13.62). L-arginine had the best discriminative ability with a bias-adjusted area under the receiver operator characteristic curve of 0.859. Conclusions: Higher serum concentrations of L-arginine and endogenous methylarginines are strongly associated with IBS in adults.]]> Wed 14 Dec 2022 09:23:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47269 Wed 11 Jan 2023 10:20:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26195 Wed 11 Apr 2018 15:00:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24880 Wed 11 Apr 2018 13:02:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30807 Wed 11 Apr 2018 11:36:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20989 Wed 11 Apr 2018 11:20:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33312 Wed 10 Oct 2018 13:14:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39273 Wed 10 Aug 2022 10:57:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46024 Wed 09 Nov 2022 15:40:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32712 Wed 09 Mar 2022 16:01:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54642 Wed 06 Mar 2024 19:02:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48761 Wed 05 Apr 2023 13:49:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49021 Wed 03 May 2023 12:31:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55026  2 neurological features, demonstrated excellent discrimination: AUC of 0.953 (95% CI: 0.916, 0.987). A predictive scoring system (total score/7) identified an optimal threshold of ≥ 3 points, with a sensitivity of 87% and specificity of 79%. Conclusions: The study identified a diagnostic support tool with four variables to predict increased risk of CAD. Validation in a clinical sample is needed to confirm variables and refine descriptors to enable clinicians to efficiently apply the tool.Optimum cutoff scores of ≥ 3/7 points will help identify those in whom CAD should be considered and further investigation instigated. The potential impact of the tool is to improve early recognition of CAD in those with acute headache or neck pain, thereby facilitating more timely medical intervention, preventing inappropriate treatment, and improving patient outcomes.]]> Wed 03 Apr 2024 15:48:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54457 Tue 27 Feb 2024 13:54:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52000 Tue 26 Sep 2023 11:29:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47638 Tue 24 Jan 2023 14:30:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32043 Tue 24 Apr 2018 13:52:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44624 P<.0001; with adjustment for infant sex and maternal body mass index). Indigenous mean birthweight percentile was 4.2 units lower (P<.0001). Adjustment for maternal age, smoking, body mass index, and infant sex reduced the difference in birthweight/percentiles to nonsignificance (12 g; P=.07). Conclusion: Disparities exist between indigenous and non-indigenous Australian infants for birthweight, birthweight percentile, and adverse outcome rates. Adjustment for smoking and maternal age removed any significant difference in birthweights and birthweight percentiles for indigenous infants. Our data indicate that birthweight percentiles should not be adjusted for indigenous ethnicity because this normalizes disadvantage; because White and indigenous Australians have diverged for approximately 50,000 years, it is likely that the same conclusions apply to other ethnic groups. The disparities in birthweight percentiles that are associated with smoking will likely perpetuate indigenous disadvantage into the future because low birthweight is linked to the development of chronic noncommunicable disease and poorer educational attainment; similar problems may affect other indigenous populations.]]> Tue 18 Oct 2022 11:09:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41967 Tue 16 Aug 2022 14:45:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41899 PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. Methods: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration. Results: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer’s disease – outcomes for which large-scale trial data were unavailable. Conclusions: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.]]> Tue 16 Aug 2022 08:27:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38956 Tue 15 Mar 2022 18:57:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43082 Tue 13 Sep 2022 12:19:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54198 Tue 13 Feb 2024 10:54:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47053 Tue 13 Dec 2022 15:25:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47020 Tue 13 Dec 2022 12:44:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20561 Tue 10 Oct 2023 08:38:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32708 Tue 05 Mar 2024 15:32:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38998 Tue 05 Apr 2022 15:19:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30822 50 loci at which common variants with minor allele frequency >5% are associated with kidney function. GWAS using more complete reference sets for imputation, such as those from The 1000 Genomes project, promise to identify novel loci that have been missed by previous efforts. To investigate the value of such a more complete variant catalog, we conducted a GWAS meta-analysis of kidney function based on the estimated glomerular filtration rate (eGFR) in 110,517 European ancestry participants using 1000 Genomes imputed data. We identified 10 novel loci with p-value < 5 × 10−8 previously missed by HapMap-based GWAS. Six of these loci (HOXD8, ARL15, PIK3R1, EYA4, ASTN2, and EPB41L3) are tagged by common SNPs unique to the 1000 Genomes reference panel. Using pathway analysis, we identified 39 significant (FDR < 0.05) genes and 127 significantly (FDR < 0.05) enriched gene sets, which were missed by our previous analyses. Among those, the 10 identified novel genes are part of pathways of kidney development, carbohydrate metabolism, cardiac septum development and glucose metabolism. These results highlight the utility of re-imputing from denser reference panels, until whole-genome sequencing becomes feasible in large samples.]]> Tue 04 Apr 2023 19:09:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34984 Tue 03 Sep 2019 18:01:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41180 Thu 28 Jul 2022 10:58:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39670 Thu 28 Jul 2022 08:10:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45230 Thu 27 Oct 2022 12:26:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45301 Thu 27 Oct 2022 09:05:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40982 Thu 21 Jul 2022 09:13:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42081 Thu 18 Aug 2022 11:12:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37057 Thu 17 Feb 2022 09:29:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30998 1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. Findings: Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA _1c (0·03%, −0·01 to 0·08), fasting insulin (0·00%, −0·06 to 0·07), and BMI (0·11 kg/m², −0·09 to 0·30). Interpretation: PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins.]]> Thu 17 Feb 2022 09:24:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50860 Thu 17 Aug 2023 11:45:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51064 Thu 17 Aug 2023 10:19:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40386 Thu 14 Jul 2022 14:30:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36656 Thu 14 Apr 2022 11:05:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33729 Thu 13 Dec 2018 15:22:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32703 Thu 12 Jul 2018 11:51:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40385 p < 0.001); about 25% of the variation in pregnancy loss was attributable to differences between clusters. Conclusion: IPV against women, including partner controlling behaviour, is significantly associated with pregnancy loss in Ethiopia. Therefore, there is a clear need to develop IPV prevention strategies and to incorporate IPV interventions into maternal health programs.]]> Thu 11 Aug 2022 15:01:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55131 Thu 11 Apr 2024 11:21:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40311 Thu 07 Jul 2022 17:03:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44088 P =.001). This association was not present (P =.83), however, when age and sex were included in the regression model. Conclusion: In the Australian Diabetes, Obesity, and Lifestyle study dataset, there was no evidence that more TV viewing is independently associated with risk of stroke, although analyses may have been underpowered.]]> Thu 06 Oct 2022 15:48:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46986 Thu 06 Jul 2023 15:13:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47006 Thu 06 Jul 2023 14:20:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33106 0.05). Conclusions: Stroke survivors with nonresolving fatigue reported reduced fatigue and improved quality of life after taking 200 mg daily treatment with modafinil.]]> Thu 03 Feb 2022 12:21:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38632 Thu 02 Dec 2021 14:27:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7294 90%) and a severe, chronic course. All participants lived in the same geographic and climatic region and most affected individuals resided with close family members, increasing uniformity of the sociocultural environment. In affected sibling pairs, power to detect linkage to small-effect risk loci was modest, but this homogeneous sample may be enriched for loci of larger effect. Conclusions: This Indian schizophrenia sample exhibits diagnostic and ethnic homogeneity with high consistency of sociocultural environmental features. These characteristics should assist efforts to identify risk genes for schizophrenia.]]> Sat 24 Mar 2018 08:42:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13924 −11, odds ratio (OR) = 1.32), with the A allele (coding for histadine) conferring elevated disease risk. The second locus is at 19q13, (P = 2.51 x 10⁻⁹, OR = 1.42 for the rs2233152 SNP near MIA and RAB4B; P = 1.68 x 10⁻¹², OR = 1.52 for rs28493229 in ITPKC), which confirms previous findings¹. The involvement of the FCGR2A locus may have implications for understanding immune activation in Kawasaki disease pathogenesis and the mechanism of response to intravenous immunoglobulin, the only proven therapy for this disease.]]> Sat 24 Mar 2018 08:24:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28089 Sat 24 Mar 2018 07:39:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25277 −11; odds ratio (OR) = 1.42, 95% confidence interval (CI) = 1.28–1.57). All four loci exhibited evidence for heterogeneity of effect across the stroke subtypes, with some and possibly all affecting risk for only one subtype. This suggests distinct genetic architectures for different stroke subtypes.]]> Sat 24 Mar 2018 07:38:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30267 n = 298,420), depressive symptoms (n = 161,460), and neuroticism (n = 170,911). We identify 3 variants associated with subjective well-being, 2 variants associated with depressive symptoms, and 11 variants associated with neuroticism, including 2 inversion polymorphisms. The two loci associated with depressive symptoms replicate in an independent depression sample. Joint analyses that exploit the high genetic correlations between the phenotypes (|ρˆ| ≈ 0.8) strengthen the overall credibility of the findings and allow us to identify additional variants. Across our phenotypes, loci regulating expression in central nervous system and adrenal or pancreas tissues are strongly enriched for association.]]> Sat 24 Mar 2018 07:33:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27532 Sat 24 Mar 2018 07:28:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38208 p = 0.02) and consumed more fruit (≥ 2 serves/day; 57.4% to 66.4%; p = 0.01) in the recent survivorship period, but were less likely to be classified in the healthy weight range (p < 0.01). The proportion of non-drinkers and non-smokers slightly increased over the survivorship period. Whole-vegetable intake did not significantly change; however, the intake of non-starchy vegetables significantly increased from pre-diagnosis (LS mean = 89.1g/day) to post-diagnosis, 6 to ≤ 9 years (LS mean = 137.1g/day), and 9 to ≤ 12 years (LS mean = 120.8g/day). There were no significant changes in the total intake of fibre, carotenoids, calcium, fat, saturated fat, vitamin C, or vitamin E observed, except for increased total energy intake (p = 0.012). Conclusion: Before diagnosis, BCSs had similar adherence to health behaviours compared to cancer-free women. Initial positive changes to health behaviours were observed post BC diagnosis, except healthy body weight, but maintenance of such changes over the long-term was poor. BCSs may benefit from additional advice and support to make healthy lifestyle choices throughout survivorship.]]> Mon 29 Jan 2024 17:55:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50014 Mon 26 Jun 2023 14:39:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32706 Mon 23 Sep 2019 11:46:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32298 Mon 23 Sep 2019 11:17:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32776 Mon 23 Sep 2019 11:07:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32805 Mon 23 Sep 2019 10:39:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39141 Mon 16 May 2022 15:36:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47386 Mon 16 Jan 2023 15:24:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53788 Mon 15 Jan 2024 10:37:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51583 Mon 11 Sep 2023 14:36:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51578 Mon 11 Sep 2023 14:28:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44210 Mon 10 Oct 2022 15:49:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44168 Mon 10 Oct 2022 10:13:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44067 Mon 10 Oct 2022 08:54:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31936 Mon 09 Apr 2018 15:04:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48080 Mon 03 Apr 2023 09:57:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46526 Fri 25 Nov 2022 09:41:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38990 Fri 25 Mar 2022 14:35:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43571 Fri 23 Sep 2022 14:03:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33268 Fri 21 Sep 2018 14:23:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33266 Fri 21 Sep 2018 14:23:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53877 Fri 19 Jan 2024 12:40:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47058 Fri 19 Apr 2024 14:52:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50542 Fri 18 Aug 2023 12:00:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48892 Fri 14 Apr 2023 15:30:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41797 5 mL, the AUC was 0.87, 0.81, and 0.66, respectively. Conclusion: Comprehensive CTP analysis increases the detection of posterior fossa lesions compared to NCCT and should be implemented as part of the routine imaging assessment in posterior fossa strokes.]]> Fri 12 Aug 2022 12:24:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41778 Fri 12 Aug 2022 12:03:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30953 Fri 03 Dec 2021 10:35:52 AEDT ]]>